{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=palifermin&page=2", "query": { "intervention": "palifermin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=palifermin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T09:41:19.295Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03042585", "title": "Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Relapsed Non Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-06", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042585" }, { "nct_id": "NCT01233921", "title": "Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Graft Versus Host Disease", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Martin, Paul", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01233921" }, { "nct_id": "NCT00267046", "title": "Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Oral Mucositis" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adriamycin (Doxorubicin)", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "15 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2005-12", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267046" }, { "nct_id": "NCT06851767", "title": "Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "X-linked Severe Combined Immunodeficiency", "X-SCID", "XSCID" ], "interventions": [ { "name": "Plerixafor", "type": "GENETIC" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Base-edited hematopoietic stem and progenitor cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "3 Years to 99 Years · Male only" }, "enrollment_count": 18, "start_date": "2025-05-09", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06851767" }, { "nct_id": "NCT00376935", "title": "Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Palifermin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2006-12", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 22, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376935" }, { "nct_id": "NCT02037347", "title": "Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Toxic Epidermal Necrolysis", "Stevens-Johnson Syndrome" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brett King", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 2, "location_summary": "Bridgeport, Connecticut • New Haven, Connecticut", "locations": [ { "city": "Bridgeport", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02037347" }, { "nct_id": "NCT02653196", "title": "A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neuroepithelial Tumor", "Solid Tumor", "Allogeneic Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy", "type": "PROCEDURE" }, { "name": "Keratinocyte Growth Factor", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 1, "start_date": "2015-09", "completion_date": "2017-08", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02653196" }, { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" }, { "nct_id": "NCT06959771", "title": "Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD40L-HyperIgM Syndrome" ], "interventions": [ { "name": "Base-edited hematopoietic stem and progenitor cells", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Base-edited T lymphocyte cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "37 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "37 Years to 120 Years · Male only" }, "enrollment_count": 1, "start_date": "2025-07-16", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959771" }, { "nct_id": "NCT01200329", "title": "High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 81, "start_date": "2011-06", "completion_date": "2018-12-06", "has_results": true, "last_update_posted_date": "2019-12-16", "last_synced_at": "2026-09-23T09:41:19.295Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200329" } ] }